Formulations for treating bladder cancer

Abstract

Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.

What is claimed is: 
     
         1 . A method of treating bladder cancer or an upper tract urothelial carcinoma (UTUC) in a patient, comprising administering liposome suspension, wherein the liposomes comprise:
 A. paclitaxel,   B. dimyristoyl phosphatidylcholine (DMPC), and   C. dimyristoyl phosphatidyl glycerol sodium (DMPG)   
       wherein the weight/weight/weight (w/w/w) ratios of (A):(B):(C) are (1):(1-2):(0.2-0.7). 
     
     
         2 . The method of  claim 1 , wherein the w/w/w ratios of (A):(B):(C) are (1):(1.4):(0.6) via intravesical administration. 
     
     
         3 . The method of  claim 1 , wherein the liposome suspension further comprises at least one of mannitol, sucrose, and trehalose. 
     
     
         4 . The method of  claim 3 , wherein the liposome suspension further comprise mannitol. 
     
     
         5 . The method of  claim 4 , wherein the w/w ratio of the (combined liposome components (A), (B), and (C)) to (mannitol) is (1):(0.15-0.8). 
     
     
         6 . The method of  claim 5 , wherein the w/w/w ratios of (A):(B):(C) are 1:(1.4):(0.6). 
     
     
         7 . The method of  claim 1 , wherein bladder cancer is treated. 
     
     
         8 . The method of  claim 7 , wherein the bladder cancer is a non-muscle invasive bladder cancer. 
     
     
         9 . The method of  claim 8 , wherein the liposome suspension is administered via intravesical administration into at least one of the ureter or renal pelvis. 
     
     
         10 . The method of  claim 1 , wherein UTUC is treated. 
     
     
         11 . The method of  claim 10 , the liposome suspension is administered via intravesical administration into at least one of the ureter or renal pelvis.